Yes, the stock price is at around $5 right now (at the moment less than).Unity Biotechnology is a biotech startup company that was co-founded by Nathaniel David in 2011 and specifically focuses on anti-aging by targeting senescent cells. If you're thinking Unity Biotechnology (NASDAQ: UBX) then you'd be absolutely correct, and deserve a pat on the back. He didn't specifically state it, but had mentioned an office park "on the outside of San Francisco" where this company has filed patents - probably where the company headquarters areĪny guesses as to what company is being teased here?.Its market cap is only around $400 million.Blackrock has 2 million shares, "The Mayo Clinic's venture capital fund has added 1.5 million shares to its portfolio".The company has patented around 140 anti-aging compounds over the years and eventually discovered a single senolytic compound "to rule them all" in 2018.So we know Nathaniel David plays a big role in the company being teased, but we need some more clues to figure out the company. The guy they're talking about here is Nathaniel David, an American scientist who got his PhD in Molecular and Cellular biology from the University of California, Berkely, and that has co-founded a number of biotech companies, including Syrrx (the company acquired by Takeda for $270 million) and Kythera (acquired by Allergan for $2.1 billion). In 2007 he discovered some way to extract fuel from pond algae.He sold one company he helped start to Takeda Pharmaceuticals for $270 million and another company that was acquired by Allergan for $2.1 billion.He "was named by the MIT Technology Review as one of the top 100 innovators in the world under 35" and went for his PhD at the University of California Berkeley.In the teaser there was a bunch of talk about one of the guys leading the company. Let's take a look at some of the clues we were given to piece this puzzle together. and potentially turn every $500 invested into $1.5 million?. what is the "tiny firm" that is going to make you filthy stinkin' rich?. a vicious cycle.įor more info on this you can watch this video: The immune system helps to get rid of these cells, but as you age more and more build up and as they build up the immune system is weakened more and more. What you want is for your cells to die and be recycled, but some turn into the unproductive "zombie cells", which are in a state of senescence - in this state they become difficult to kill.Īnd not only are they unproductive in this state, but they also excrete toxins and help to bring more cells going into this state. and old cells then either are recycled or turn into these "zombie cells". Well, the senolytic pills help to get rid of old "zombie cells" that build up as we age and cause damage and harm.Ĭells divide and multiply, but eventually reach their " Hayflick limit", which is the limit to the amount of times that cells can do this. industries are and how much potential a pill like this has.Īccording to the numbers he gives, all the different areas of healthcare that this single pill could disrupt sum up to a market of around $15 trillion a year.Īccording to Stutman, these new pills could cure aging and sick people forever. Unity Biotechnology shares dropped 60% on August 17, 2020, after the company reported disappointing results from a clinical trial involving its then lead drug candidate, UBX0101, in patients with moderate-to-severe painful osteoarthritis.Stutman talks about how big the diabetes, high blood pressure, heart disease, etc. On May 3, 2018, the company went public on the Nasdaq exchange, raising $85 million at a market capitalization of $700 million. They also include UBX 1967, a preclinical product targeting ophthalmologic diseases. The company then reported in April 2023 results from its Phase 2 study demonstrating that a single injection of UBX1325 resulted in a statistically significant and clinically meaningful improvement in vision through 48 weeks. In July 2022, the company reported positive results from its Phase 1 study. The company's products in development include UBX1325, which targets Bcl-xL, a mechanism to eliminate senescent cells in age-related eye diseases. Unity Biotechnology is a publicly traded American biotechnology company that develops drugs that target senescent cells.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |